Related Experiment Video

Updated: Dec 27, 2025

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.3K

Novel targeted therapies for the management of liver fibrosis

Juan P Trivella1, Paul Martin2, Andres F Carrion2

  • 1Division of Gastroenterology and Hepatology, Medical College of Wisconsin, Milwaukee, WI, USA.

Expert Opinion on Emerging Drugs
|February 27, 2020
PubMed

Insights

Novel anti-fibrotic drugs show promise for reversing liver fibrosis, a major cause of cirrhosis mortality. Further clinical trials are needed to confirm the efficacy and safety of these agents.

Area of Science:

  • Hepatology
  • Fibrosis Research
  • Pharmacology

Background:

  • Prolonged liver injury leads to fibrosis and cirrhosis, a significant cause of global mortality.
  • Fibrogenesis is reversible if addressed early, driving the search for new anti-fibrotic therapies.
  • Current research focuses on identifying therapeutic targets and developing novel anti-fibrotic agents.

Purpose of the Study:

  • To review recent clinical data on anti-fibrotic drugs.
  • To summarize the progress in the development of agents targeting liver fibrosis.
  • To discuss the future directions in anti-fibrotic therapy.

Main Methods:

  • Review of clinical data on anti-fibrotic drugs.
  • Summary of preclinical findings and early clinical studies.
  • Analysis of ongoing clinical trials and combination therapy approaches.

Main Results:

  • Several anti-fibrotic agents, including monoclonal antibodies, targeted conjugates, and small molecules, are in clinical development.
  • Progress has been made in identifying potential therapeutic targets for fibrogenesis.
  • Most data are from preclinical and early-phase clinical studies.

Conclusions:

  • Anti-fibrotic agents represent a promising therapeutic strategy for liver fibrosis.
  • Larger clinical trials are essential to validate the efficacy and safety of these agents.
  • Combination therapies targeting diverse fibrogenesis pathways warrant future investigation.
Keywords:
Anti-fibroticscirrhosisfibrogenesishepatic stellate cellsliver fibrosis

More Related Videos

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.9K
Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis08:56

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis

Published on: February 10, 2015

54.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
167
Ultrasound II: Endoscopic Ultrasound and FibroScan01:25

Ultrasound II: Endoscopic Ultrasound and FibroScan

Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
433
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
130
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
391
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
386